Macrogenics, Inc.

Cytomx Therapeutics, Inc.

Raven Biotechnologies, Inc.

Ptm Therapeutics, Inc.

Tony Liang

Luc Roland Desnoyers

Jennie Powell Mather

Henry Bernard Lowman

Andrei William Konradi

Deryk T Loo

Shweta Singh

Annie Yang Weaver

Xiaolin Xu

Leonard G Presta

Ronghao Li

Jennifer Cheng

The invention relates generally to compositions and methods for conjugating antibodies and activatable antibodies, and methods of partially reducing antibodies and/or activatable antibodies prior to conjugation, e.g., thiol-based conjugation, with an agent, e.g., a therapeutic and/or diagnostic agent.

Compositions and methods for conjugating activatable antibodies

The present disclosure provides antibodies, or an antigen binding portion thereof, that bind to sLeA and sLeC, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.

Anti-glycan antibodies and uses thereof

The invention relates generally to antibodies and antigen-binding fragments thereof that bind activatable antibodies and/or conjugated activatable antibodies and methods of making and using these antibodies that bind activatable antibodies and/or conjugated activatable antibodies.

Antibodies that bind activatable antibodies and methods of use thereof

The invention provides the identification and characterization of disease and cancer-associated epitope, KID3. The invention also provides a family of monoclonal antibodies that bind to KID3, methods of diagnosing and treating various human cancers and diseases that express KID3.

KID3 and KID3 antibodies that bind thereto

The invention provides the identification and characterization of a disease and cancer-associated antigen, TES7. The invention also provides a family of monoclonal antibodies that bind to antigen TES7, methods of diagnosing and treating various human cancers and diseases with TES7.

TES7 and antibodies that bind thereto

The invention provides the identification and characterization of disease and cancer-associated antigen, TES7. The invention also provides a family of monoclonal antibodies that bind to antigen TES7, methods of diagnosing and treating various human cancers and diseases that express TES7.

Provided herein is disclosure about the identification and characterization of disease and cancer associated antigen PIPA. The invention also provides a family of monoclonal antibodies that bind to antigen PIPA, and methods of diagnosing and treating various human cancers and diseases that express PIPA.

Growing community of inventors

San Mateo, CA, United States of America

Tony Liang